IGM Biosciences Future Growth
Future criteria checks 2/6
IGM Biosciences is forecast to grow earnings and revenue by 3% and 51.8% per annum respectively. EPS is expected to grow by 11.8% per annum. Return on equity is forecast to be -175.5% in 3 years.
Key information
3.0%
Earnings growth rate
11.8%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 51.8% |
| Future return on equity | -175.5% |
| Analyst coverage | Good |
| Last updated | 19 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 13 | -150 | -155 | -111 | 7 |
| 12/31/2025 | 7 | -154 | -143 | -108 | 9 |
| 12/31/2024 | 3 | -208 | -175 | -158 | 8 |
| 9/30/2024 | 3 | -220 | -173 | -166 | N/A |
| 6/30/2024 | 3 | -220 | -176 | -168 | N/A |
| 3/31/2024 | 2 | -237 | -195 | -184 | N/A |
| 12/31/2023 | 2 | -246 | -205 | -192 | N/A |
| 9/30/2023 | 2 | -238 | -196 | -182 | N/A |
| 6/30/2023 | 2 | -234 | -196 | -182 | N/A |
| 3/31/2023 | 2 | -229 | -29 | -18 | N/A |
| 12/31/2022 | 1 | -221 | -16 | -6 | N/A |
| 9/30/2022 | 1 | -219 | -13 | -3 | N/A |
| 6/30/2022 | 0 | -205 | -6 | 3 | N/A |
| 3/31/2022 | N/A | -185 | -146 | -136 | N/A |
| 12/31/2021 | N/A | -165 | -138 | -125 | N/A |
| 9/30/2021 | N/A | -139 | -131 | -112 | N/A |
| 6/30/2021 | N/A | -115 | -116 | -93 | N/A |
| 3/31/2021 | N/A | -95 | -101 | -79 | N/A |
| 12/31/2020 | N/A | -81 | -85 | -68 | N/A |
| 9/30/2020 | N/A | -72 | -68 | -57 | N/A |
| 6/30/2020 | N/A | -61 | -62 | -57 | N/A |
| 3/31/2020 | N/A | -53 | -56 | -53 | N/A |
| 12/31/2019 | N/A | -43 | -47 | -45 | N/A |
| 9/30/2019 | N/A | -37 | -41 | -39 | N/A |
| 6/30/2019 | N/A | -34 | -31 | -30 | N/A |
| 3/31/2019 | N/A | -27 | -26 | -24 | N/A |
| 12/31/2018 | N/A | -23 | -21 | -20 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1K0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1K0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1K0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1K0's revenue (51.8% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 1K0's revenue (51.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1K0 is forecast to be unprofitable in 3 years.